A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study is designed for multi-center, randomized, double-masked, active-controlled study to
evaluate the longer interval of intravitreal injection of IBI302 in subjects with neovascular
age-related macular degeneration.